Latest news with #BHV-7000
Yahoo
27-05-2025
- General
- Yahoo
Austin doctor studying a new kind of medication for major depressive disorder
Austin psychiatrist Dr. Donald J. Garcia is enrolling patients in a study on a new kind of medication for major depressive disorder. While drug companies have created many medications that help increase serotonin, that neurotransmitter chemical that is our natural mood stabilizer in the brain, only about 60% to 70% of patients will respond to those medications, Garcia said. The major depressive disorder medication, BHV-7000, is different than those that focus on serotonin because it focuses on potassium channels, which help regulate the activity of neurons in the brain. The channels "could help calm the brain and get it back to a normal state," Garcia said. "This is an interesting hypothesis." Garcia and his company Austin Clinical Trial Partners are enrolling up to 306 people ages 18 to 75 in a trial to study the drug, which is made by the biopharmaceutical company Biohaven. For the trial, Garcia is looking for people who are having a major depressive disorder episode lasting two months up to 24 months. They must stop taking their depression medication at least two weeks prior to enrolling in the study, and cannot be having suicidal thoughts. Interested participants will receive a physical exam and testing to make sure they are medically stable before beginning the study. Garcia noted that having major depressive disorder doesn't just mean you are depressed, which is a description of a mood state. It's "depression plus other symptoms that become a clinical syndrome," he said. Those symptoms may include insomnia, a loss of interest in things you used to love, or simply not taking pleasure in daily life. They are constant, lasting for longer than just one or two days, and can creep up on you, Garcia said. Can a magnet help my mental health? How transcranial magnetic stimulation works in Austin. Half of the people in the study will receive the BHV-7000 medication and half will receive a placebo. No one will know which group they have been assigned to. Enrollees will continue taking the medication or the placebo for six weeks. After that part of the study concludes, they may opt to continue with the study and would be guaranteed to receive the medication for 52 weeks. Garcia said he feels better knowing that he can offer the medication to all participants after the initial study period ends. While in the study, participants will receive free psychiatric care. Such clinical trials "bring us closer to the understanding of how depression might come about," Garcia said. "It might be caused by a number of different mechanisms or issues." Dell Medical School clinic at UT Austin joins global bipolar study for treatments To find out more about the study and if they qualify, people can visit or This article originally appeared on Austin American-Statesman: Austin doctor studying major depressive disorder medication
Associated Press
14-04-2025
- Business
- Associated Press
BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--Apr 13, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biohaven Ltd. ('Biohaven' or 'the Company') (NYSE: BHVN ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Biohaven announced its financial results for Q4 and full year 2024 on March 3, 2025. The Company reported a larger loss than expected for the quarter. The Company also disclosed that data from its late-stage clinical trial of drug candidate BHV-7000 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure.' Based on this news, shares of Biohaven fell by 13.77% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Schall Law Firm Copyright Business Wire 2025. PUB: 04/13/2025 10:04 PM/DISC: 04/13/2025 10:04 PM
